Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Intern Med J ; 45(9): 944-50, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26011062

ABSTRACT

BACKGROUND: The management of children with congenital heart disease (CHD) has improved over recent decades and several patients surviving with CHD into adulthood are increasing. In developed countries, there are now as many adults as there are children living with CHD. Pulmonary arterial hypertension (PAH) occurs in ∼ 5% of patients with CHD. AIM: We aimed to understand the characteristics and outcomes of this emerging population. METHODS: We collected data retrospectively and prospectively from 12 contributing centres across Australia and New Zealand (2010-2013). Patients were included if they had been diagnosed with PAH and CHD and had been seen once in an adult centre after 1 January 2000. RESULTS: Of 360 patients with CHD-PAH, 60% were female and 90% were New York Heart Association functional class II or III at the time of adult diagnosis of PAH. Mean age at diagnosis of PAH in adulthood was 31.2 ± 14 years, and on average, patients were diagnosed with PAH 6 years after symptom onset. All-cause mortality was 12% at 5 years, 21% at 10 years and 31% at 15 years. One hundred and six patients (30%) experienced 247 hospitalisations during 2936 patient years of follow up. Eighty-nine per cent of patients were prescribed PAH specific therapy (mean exposure of 4.0 years). CONCLUSIONS: Adults with PAH and CHD often have this diagnosis made after significant delay, and have substantial medium-term morbidity and mortality. This suggests a need for children transitioning to adult care with CHD to be closely monitored for this complication.


Subject(s)
Antihypertensive Agents/administration & dosage , Endothelin Receptor Antagonists/administration & dosage , Heart Defects, Congenital/epidemiology , Hypertension, Pulmonary/epidemiology , Registries , Adult , Australia/epidemiology , Combined Modality Therapy , Diuretics , Female , Follow-Up Studies , Heart Defects, Congenital/complications , Heart Defects, Congenital/physiopathology , Humans , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/physiopathology , Male , New Zealand/epidemiology , Quality of Life , Retrospective Studies , Risk Factors
2.
Clin Exp Rheumatol ; 32(6 Suppl 86): S-133-7, 2014.
Article in English | MEDLINE | ID: mdl-24564981

ABSTRACT

OBJECTIVES: To determine the prevalence and correlates of antiphospholipid antibodies (APLA) in systemic sclerosis (SSc). METHODS: Nine hundred and forty SSc patients were tested for APLA using an ELISA assay at recruitment. Clinical manifestations were defined as present, if ever present from SSc diagnosis. Logistic regression analysis was used to determine the associations of APLA. RESULTS: One or more types of APLA were present in 226 (24.0%) patients. Anticardiolipin (ACA) IgG (ACA-IgG) antibodies were associated with right heart catheter-diagnosed pulmonary arterial hypertension (PAH), with higher titres corresponding with a higher likelihood of PAH (moderate titre (20-39 U/ml) ACA-IgG odds ratio [OR] 1.70, 95% CI: 1.01-2.93, p=0.047; high titre (>40 U/ml) ACA-IgG OR 4.60, 95% CI:1.02-20.8, p=0.047). Both ACA-IgM (OR 2.04, 95% CI: 1.4-3.0, p<0.0001) and ACA-IgG (OR 1.84, 95% CI: 1.2-2.8, p=0.005) were associated with interstitial lung disease (ILD). Increasing ACA-IgM and IgG titres were associated with increased likelihood of ILD. ACA-IgG was a marker of coexistent pulmonary hypertension and ILD (ILD-PH) (OR 2.10, 95% CI: 1.1-4.2, p=0.036). We also found an association between ACA-IgG and digital ulcers (OR 1.76, 95% CI: 1.16-2.67, p=0.008) and ACA-IgM and Raynaud's phenomenon (OR 2.39, 95% CI: 1.08-5.27, p=0.031). There was no association between APLA and SSc disease subtype, peak skin score, presence of other autoantibodies, mortality or other disease manifestations. CONCLUSIONS: The association of APLA with PAH, ILD, ILD-PH, Raynaud's phenomenon and digital ulcers suggests that endothelial abnormalities and small vessel thrombosis may be important in the pathogenesis of these disease features.


Subject(s)
Antibodies, Anticardiolipin/immunology , Heart Diseases/immunology , Hypertension, Pulmonary/immunology , Lung Diseases, Interstitial/immunology , Scleroderma, Systemic/immunology , Aged , Antibodies, Antiphospholipid/immunology , Cohort Studies , Female , Hand Dermatoses/etiology , Hand Dermatoses/immunology , Heart Diseases/etiology , Humans , Hypertension, Pulmonary/etiology , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Logistic Models , Lung Diseases, Interstitial/etiology , Male , Middle Aged , Prospective Studies , Raynaud Disease/etiology , Raynaud Disease/immunology , Scleroderma, Systemic/complications , Skin Ulcer/etiology , Skin Ulcer/immunology
3.
Intern Med J ; 44(2): 114-23, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24383793

ABSTRACT

On 5 May 2013 it was World Pulmonary Hypertension (PHT) Day marking three decades on from the first reported deaths in an epidemic because of toxic rapeseed (canola) oil. This epidemic provided the impetus to the first World Health Organization to set up a world symposia. World leaders of PHT met for the fifth time in Nice, France in February 2013. Although we wait the official proceedings, this meeting provides us opportunity to reflect on the current situation in Australia and New Zealand, and examine the implications for our two countries. PHT remains difficult to identify, delays in patient diagnosis persist, and breathlessness remains dominant in the diagnosis of all causes of PHT. This review examines some of the recent changes in diagnosis, our understanding of the emerging expanding epidemiology data and the patient's journeys through the healthcare system. We also review the current treatment options on monotherapy and in poly-pharmacy or combination therapy, along with the strategic management implications of the lack of funded combination therapy associated with prognosis.


Subject(s)
Antihypertensive Agents/therapeutic use , Dyspnea/etiology , Hypertension, Pulmonary , Congresses as Topic , Delayed Diagnosis/prevention & control , Disease Management , Humans , Hypertension, Pulmonary/classification , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/physiopathology , Hypertension, Pulmonary/therapy , Prognosis , Randomized Controlled Trials as Topic
4.
Int J Clin Pract ; 66(11): 1117-24, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23067036

ABSTRACT

BACKGROUND: Pulmonary hypertension (PH) is a condition that affects more than 25 million individuals worldwide and causes premature disability and death. Despite advances in our understanding of this condition, education and training of health professionals has not kept pace with the rapid changes in diagnosis and treatment. The net effects of this gap between advancing knowledge and limited educational opportunity likely include clinically significant delays in both the diagnosis and commencement of effective evidence-based treatment - an unacceptable outcome for patients with a lethal condition. AIM: The Actelion Clinical Excellence Programme (ACEP) is an e-learning postgraduate curriculum, the purpose of which is to educate and mentor healthcare professionals, both theoretically and practically, in the diagnosis and treatment of patients with all forms of PH. This article reports on the development and delivery of the programme and outcomes from its first year of operation. RESULTS: Forty-three healthcare professionals from 22 institutions were enroled in the first iteration of the programme. In the 6 months from May to October 2011, participants successfully completed 285 lectures and/or activities. Overall, the programme was considered easily accessible, comprehensive in terms of both quality and quantity, provided an efficient means of self-paced learning, and was a highly regarded as reference source. Ninety-five per cent of participants said that they intended to change their clinical practice as a result of the information presented in the programme. CONCLUSION: ACEP represents a successful physician-industry partnership, which has resulted in a significant impact on clinical teaching and awareness of PH.


Subject(s)
Education, Medical, Graduate/organization & administration , Hypertension, Pulmonary/therapy , Internet , Pulmonary Medicine/education , Australia , Clinical Competence/standards , Curriculum , Evidence-Based Medicine/education , Humans , New Zealand , Program Evaluation
5.
Intern Med J ; 42(8): 874-9, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22212153

ABSTRACT

BACKGROUND/AIMS: Pulmonary arterial hypertension (PAH) frequently accompanies childhood congenital heart disease (CHD) and may persist into adult life. The advent of specific PAH therapies for PAH prompted formation of a national Australian and New Zealand registry in 2010 to document the incidence, demographics, presentation and outcomes for these patients. METHODS: This multicentre, prospective, web-based registry enrols patients with CHD-associated PAH being followed in a tertiary centre. The inclusion criteria stipulated patient age ≥16 years, a measured mean pulmonary arterial pressure >25 mmHg at rest or echocardiographical evidence of PAH or a diagnosis of Eisenmenger syndrome, and followed since 1 January 2000. A single observer collected standardised data during a series of site visits. RESULTS: Of the first 50 patients enrolled, 30 (60%) were female. The mean age (standard deviation (SD)) at the time of PAH diagnosis or confirmation in an adult centre was 27.23 (10.07) years, and 32 (64%) patients are currently aged >30 years. Fourteen (28%) patients were in World Health Organization Functional Class II and 36 (72%) in Class III at the time of diagnosis. Forty-seven of 50 (94%) had congenital systemic-pulmonary shunts, and 36 (72%) never underwent intervention. Thirteen (26%) had Down syndrome. Confirmation of PAH by recent cardiac catheterisation was available in 30 (60%) subjects. During follow up, a total of 32 (64%) patients received a PAH-specific therapy. CONCLUSIONS: CHD associated with PAH in adult life has resulted in a new population with unique needs. This registry will allow documentation of clinical course and long-term outcomes for these patients.


Subject(s)
Heart Defects, Congenital/epidemiology , Hypertension, Pulmonary/epidemiology , Registries , Adult , Female , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/therapy , Humans , Hypertension, Pulmonary/diagnosis , Hypertension, Pulmonary/therapy , Male , Prospective Studies , Young Adult
6.
Intern Med J ; 41(3): 235-44, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21118410

ABSTRACT

BACKGROUND: Several cellular pathways are implicated in the pathogenesis of pulmonary arterial hypertension (PAH) and attempts to arrest disease progression with a single drug would not be expected to succeed in the medium term. In clinical practice, combination therapy is often used in patients deteriorating on monotherapy, despite the absence of firm evidence from randomized controlled controls. METHODS: From January 2005 to August 2009, 112 patients with World Health Organisation Functional Class (FC) II-IV PAH deteriorating on monotherapy received non-parenteral combination therapy at six Australian PAH expert hospitals. Combination therapy included bosentan, sitaxentan, ambrisentan, iloprost and sildenafil. Data were prospectively collected for survival status, 6-min walk distance, FC and echocardiographic parameters at the start of monotherapy through to commencement of combination therapy and at 6-monthly intervals thereafter. RESULTS: After varying periods of monotherapy (18.7±13.4onths), survival estimates on combination therapy were 88%, 71% and 61% for the additional 1, 2 and 3years respectively. Survival on dual therapy in patients with idiopathic PAH/familial PAH was 93% at 1year and 79% at 2years, and for scleroderma-related PAH, 72% at 1 year and 48% at year 2 after initiation of combination therapy. In survivors, dual therapy reversed the deterioration in FC, from 3.1±0.6 on monotherapy to 2.2±0.6 at 12months. Similarly, dual therapy improved 6-min walk distance from 316±119m to 406±129m at 12months, and sequential echocardiography demonstrated a fall in pulmonary artery systolic pressure and improved right ventricular function. CONCLUSIONS: Dual non-parenteral therapy appears safe and effective and should be considered for PAH patients who are deteriorating on monotherapy to improve long-term outcomes.


Subject(s)
Cooperative Behavior , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/mortality , Adult , Aged , Australia/epidemiology , Bosentan , Drug Therapy, Combination , Familial Primary Pulmonary Hypertension , Female , Humans , Male , Middle Aged , Phenylpropionates/administration & dosage , Piperazines/administration & dosage , Prospective Studies , Purines/administration & dosage , Pyridazines/administration & dosage , Sildenafil Citrate , Sulfonamides/administration & dosage , Sulfones/administration & dosage , Survival Rate/trends , Young Adult
7.
Intern Med J ; 40(10): 716-20, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21038537

ABSTRACT

Reversible posterior leukoencephalopathy syndrome (RPLS) is a potentially devastating early complication of calcineurin inhibitor (CNI) therapy in solid organ transplantation. Management centres on cessation of CNI therapy; however, this strategy is complicated in lung transplantation because of the threat of allograft rejection, or, if CNI is replaced with mammalian target of rapamycin-based immunosuppression, poor wound healing and bronchial dehiscence. We describe four cases of RPLS after lung transplantation, emphasizing the diagnostic and management approach required to maintain a healthy allograft and ensure that RPLS is, as the name suggests, reversible.


Subject(s)
Immunosuppression Therapy , Lung Transplantation , Posterior Leukoencephalopathy Syndrome/diagnosis , Posterior Leukoencephalopathy Syndrome/therapy , Adolescent , Adult , Disease Management , Female , Graft Survival/immunology , Humans , Immunosuppression Therapy/adverse effects , Immunosuppression Therapy/methods , Lung Transplantation/adverse effects , Lung Transplantation/immunology , Male , Middle Aged , Posterior Leukoencephalopathy Syndrome/immunology , Retrospective Studies
8.
Heart Lung Circ ; 19(10): 595-600, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20728407

ABSTRACT

INTRODUCTION: Traditionally, treatment options for patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) are limited. Bosentan has been shown to improve pulmonary haemodynamics and exercise tolerance short term but long term clinical studies are lacking. AIM: To report long term efficacy and safety data with endothelin receptor antagonists (ERA) in patients with PAH associated CHD. METHODS: Prospective, open label, uncontrolled, single centre study of 53 patients (33 females, 17 Trisomy 21, mean age 34 ± 12 years) prescribed ERA (48 bosentan, 5 sitaxentan) from 2003 to August 2009. Outcome measurements of oxygen saturation (SaO2), WHO functional class, 6-minute walk test distance (6MWD) and adverse events were analysed. RESULTS: Mean duration of therapy was 15 ± 13 months in 53 patients with CHD. Four patients failed ERA, seven died (five progressive RHF) and one delisted from transplantation. No abnormal liver transaminases occurred on bosentan, with one case on sitaxentan. After 3, 6, 12, 18 and 24 months of treatment a significant improvement was seen in WHO functional class (mean 3.15 vs 2.8 vs 2.5 vs 2.5 vs 2.4 vs 2.4; p<0.01) and 6MWD (344 ± 18 vs 392 ± 17 vs 411 ± 17 vs 420 ± 17 vs 442 ± 18 vs 417 ± 23: p<0.0005, p<0.01) compared with baseline. The Trisomy 21 and PAH-CHD showed a significant improvement in 6MWD at 6 and 12 months (263 ± 24 vs 348 ± 29 vs 360 ± 32, p<0.01, p<0.05) respectively. No changes in SaO2, BNP, RV or LV function were demonstrated during follow-up. CONCLUSION: This large single centre study demonstrates that endothelin receptor antagonism is an effective and safe treatment in PAH associated CHD with or without Trisomy 21. The improvements in exercise tolerance are similar to reported benefits in other forms of PAH.


Subject(s)
Antihypertensive Agents/therapeutic use , Down Syndrome , Endothelin Receptor Antagonists , Heart Defects, Congenital/complications , Hypertension/drug therapy , Sulfonamides/therapeutic use , Adult , Bosentan , Confidence Intervals , Exercise Test , Exercise Tolerance , Female , Heart Defects, Congenital/pathology , Humans , Male , Prospective Studies , Pulmonary Artery/drug effects , Pulmonary Artery/pathology , Time Factors , Walking
9.
Heart Lung Circ ; 18(3): 222-5, 2009 Jun.
Article in English | MEDLINE | ID: mdl-18378190

ABSTRACT

We describe a series of cases referred to our institution with working diagnoses of chronic thrombo-embolic pulmonary hypertension (CTEPH) for consideration of surgical pulmonary thrombo-endarterectomy (PTE). Investigations in two cases revealed extrinsic compression of the pulmonary arteries from massive mediastinal lymphadenopathy (mediastinal fibrosis) due to underlying sarcoidosis. Angioplasty and stenting of the pulmonary arteries were performed in all cases with sustained haemodynamic and functional improvement. This highlights the value of new imaging modalities in delineating causes of pulmonary hypertension, and demonstrates an interventional approach for selected cases.


Subject(s)
Angioplasty, Balloon , Hypertension, Pulmonary/etiology , Mediastinal Diseases/complications , Pulmonary Artery/surgery , Sarcoidosis/complications , Aged , Humans , Hypertension, Pulmonary/surgery , Male , Mediastinal Diseases/diagnosis , Pulmonary Artery/physiopathology , Sarcoidosis/diagnosis , Stents
10.
Intern Med J ; 38(8): 657-67, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18808561

ABSTRACT

Pulmonary thromboembolism (PE) is the third most frequent cause of cardiovascular death after ischaemic heart disease and stroke. In fatal PE, 2/3 of patients die within first hour of presentation. There is a clinical impetus to rapidly recognize, risk-stratify and appropriately treat patients with acute severe PE. Current recommendations present conflicting classification systems, and there is often some confusion in the clinical evaluation and management of patients with acute severe PE. This review presents a series of real clinical cases, which illustrate the available treatment options, ranging from conservative therapy to thrombolysis through to percutaneous catheter fragmentation and open surgical embolectomy. We evaluate the evidence for the various strategies and propose an algorithm for clinicians with a focus on early risk stratification and timely referral. This is particularly relevant to regional and remote centres, as well as secondary and tertiary institutions.


Subject(s)
Pulmonary Embolism/diagnosis , Pulmonary Embolism/therapy , Acute Disease , Adult , Female , Fibrinolytic Agents/therapeutic use , Humans , Male , Middle Aged , Pulmonary Embolism/drug therapy , Severity of Illness Index , Thrombolytic Therapy/methods , Tissue Plasminogen Activator/therapeutic use , Treatment Outcome
11.
J Heart Lung Transplant ; 26(8): 850-6, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17692791

ABSTRACT

BACKGROUND: Ischemia-reperfusion injury (IRI) is a prominent cause of primary graft failure after lung transplantation and is associated with an altered surfactant profile. Experimental animal studies have found that replacement with exogenous surfactant administered via fiber-optic bronchoscopy (FOB) enhanced recovery from IRI with improved pulmonary compliance and gas exchange after lung transplantation. We report our clinical experience with FOB instillation of surfactant in severe IRI after human lung transplantation. METHODS: This study is a retrospective review of 106 consecutive lung or heart-lung transplants performed at a single institution. Severe IRI was defined as diffuse roentgenographic alveolar infiltrates, worsening hypoxemia and decreased lung compliance within 72 hours of lung transplantation. One vial of surfactant (20 mg/ml phospholipid) was instilled into each segmental bronchus upon diagnosis of IRI. RESULTS: Six patients (5 bilateral sequential and 1 re-do heart-lung transplant), mean age 46 years, were diagnosed with IRI and surfactant was administered at a mean of 37 hours (range 2.3 to 98) post-transplant. Mean graft ischemia time was 376 minutes (range 187 to 625) and cardiopulmonary bypass time 174 minutes (range 0 to 210). Mean Pao(2) [mm Hg]/Fio(2) ratio before and 48 hours after surfactant instillation was 70 and 223, respectively. Significant resolution of radiologic infiltrates was evident in all cases within 24 hours. Successful extubation occurred at a mean of 13.5 days and survival is presently 100% at 19 months (range 3 to 54). CONCLUSIONS: Bronchoscopic instillation of surfactant improves oxygenation and prognosis after severe IRI in lung transplant recipients. It represents a cost-effective, relatively non-invasive therapeutic alternative to extracorporeal membrane oxygenation.


Subject(s)
Biological Products/administration & dosage , Lung Transplantation , Lung/blood supply , Pulmonary Surfactants/administration & dosage , Reperfusion Injury/drug therapy , Adult , Bronchoscopy , Female , Fiber Optic Technology , Follow-Up Studies , Humans , Instillation, Drug , Male , Middle Aged , Optical Fibers , Radiography, Thoracic , Reperfusion Injury/complications , Reperfusion Injury/diagnostic imaging , Respiratory Insufficiency/surgery
12.
J Med Genet ; 40(12): 865-71, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14684682

ABSTRACT

BACKGROUND: Mutations of the transforming growth factor beta (TGFbeta) receptor components ENDOGLIN and ALK-1 cause the autosomal dominant vascular disorder hereditary haemorrhagic telangiectasia (HHT). Heterozygous mutations of the type II receptor BMPR2 underlie familial primary pulmonary hypertension. OBJECTIVE: To investigate kindreds presenting with both pulmonary hypertension and HHT. METHODS: Probands and families were identified by specialist pulmonary hypertension centres in five countries. DNA sequence analysis of ALK-1, ENDOGLIN, and BMPR2 was undertaken. Cellular localisation was investigated by heterologous overexpression of mutant constructs in both BAEC and HeLa cells. The impact of a novel sequence variant was assessed through comparative analysis and computer modelling. RESULTS: Molecular analysis of 11 probands identified eight missense mutations of ALK-1, one of which was observed in two families. Mutations were located within exons 5 to 10 of the ALK-1 gene. The majority of ALK-1 mutant constructs appeared to be retained within the cell cytoplasm, in the endoplasmic reticulum. A novel GS domain mutation, when overexpressed, reached the cell surface but is predicted to disrupt conformational changes owing to loss of a critical hydrogen bond. Two novel missense mutations were identified in ENDOGLIN. CONCLUSIONS: The association of pulmonary arterial hypertension and HHT identifies an important disease complication and appears most common among subjects with defects in ALK-1 receptor signalling. Future studies should focus on detailed molecular analysis of the common cellular pathways disrupted by mutations of ALK-1 and BMPR2 that cause inherited pulmonary vascular disease.


Subject(s)
Activin Receptors, Type I/genetics , Hypertension, Pulmonary/genetics , Telangiectasia, Hereditary Hemorrhagic/complications , Activin Receptors, Type I/analysis , Activin Receptors, Type I/chemistry , Activin Receptors, Type II , Adolescent , Adult , Aged , Amino Acid Sequence , Antigens, CD , Bone Morphogenetic Protein Receptors, Type II , DNA Mutational Analysis , Endoglin , Endoplasmic Reticulum/chemistry , Female , Genetic Predisposition to Disease , Humans , Hypertension, Pulmonary/diagnosis , Male , Middle Aged , Models, Molecular , Mutation, Missense , Protein Serine-Threonine Kinases/genetics , Receptors, Cell Surface , Structural Homology, Protein , Telangiectasia, Hereditary Hemorrhagic/diagnosis , Telangiectasia, Hereditary Hemorrhagic/genetics , Vascular Cell Adhesion Molecule-1/genetics
13.
Eur Respir J ; 12(2): 301-8, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9727778

ABSTRACT

Pulmonary surfactant abnormalities have consistently been documented in patients with acute lung injury (ALI), however, there is little evidence directly correlating them to altered respiratory mechanics. To explore this further, surfactant composition was measured in lung aspirate fluid collected on 15 occasions from 10 patients with ALI. The composition was compared with lung aspirate fluid from 11 intubated patients prior to elective cardiac surgery (CS), and bronchoalveolar lavage fluid from 16 normal subjects. In both the ALI and cardiac groups the proportion of disaturated phospholipids (DSP) and phosphatidylcholine was reduced. Plasma levels of surfactant proteins-A and -B (SP-A and -B) were elevated, but were unrelated to alveolar surfactant levels. In the ALI group, and the ALI + CS group, DSP, normalized to the total phospholipid content, sphingomyelin (SPH), and urea, showed strong direct correlations with arterial oxygen tension/inspiratory oxygen fraction (all p < or = 0.01). In the ALI group, normalized DSP was also directly related to the elastance of the positive end-expiratory pressure-induced increase in the end-expiratory lung volume (all p < or = 0.02), and indirect correlations were found with a measure of lung overinflation (%E2; all p < or = 0.01). We conclude that surfactant composition correlates with lung function abnormalities in acute lung injury and cardiac patients, and that both groups had elevated plasma surfactant proteins-A and -B levels, consistent with a concurrent increase in alveolocapillary permeability.


Subject(s)
Oxygen/blood , Pulmonary Surfactants/chemistry , Respiratory Distress Syndrome/metabolism , Respiratory Mechanics/physiology , Blood-Air Barrier/physiology , Bronchoalveolar Lavage Fluid/chemistry , Case-Control Studies , Heart Diseases/metabolism , Heart Diseases/physiopathology , Humans , Intubation, Intratracheal , Pulmonary Surfactants/metabolism , Respiratory Distress Syndrome/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...